Principal Financial Group Inc. Sells 865 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Principal Financial Group Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,625 shares of the biopharmaceutical company's stock after selling 865 shares during the quarter. Principal Financial Group Inc. owned 0.12% of Regeneron Pharmaceuticals worth $82,212,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.8%

NASDAQ:REGN traded up $9.64 during mid-day trading on Tuesday, hitting $547.75. The company had a trading volume of 847,049 shares, compared to its average volume of 909,523. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The business's fifty day moving average is $547.51 and its two-hundred day moving average is $623.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a market cap of $59.14 billion, a P/E ratio of 13.94, a P/E/G ratio of 1.98 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the company posted $9.55 EPS. The company's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Finally, Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.